SCHEMBL13855513

SCHEMBL13855513

CN(C)CC(c1ccc(Cl)cc1)c1ccc(Br)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 5/20 0.53
HTR2A P28223 5/20 0.53
TDP1 Q9NUW8 1/20 0.52
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
SLC6A2 P23975 6/20 0.44
SLC6A4 P31645 6/20 0.44
CHRM2 P08172 5/20 0.44
CHRM1 P11229 5/20 0.44
SLC6A3 Q01959 5/20 0.44
KCNH2 Q12809 4/20 0.44
HRH3 Q9Y5N1 4/20 0.44
ADRA2B P18089 3/20 0.44
DRD1 P21728 3/20 0.44
CYP2D6 P10635 2/20 0.44
NFKB1 P19838 2/20 0.44
THPO P40225 2/20 0.44
HTR2C P28335 2/20 0.44
SCN1A P35498 2/20 0.44
SCN2A Q99250 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1979230 0.90 HTR2A (0.64) HRH1HTR2ATDP1LMNASMN1; SMN2
SCHEMBL16036062 0.82 KMT2A (0.46) HRH1HTR2ATDP1LMNASLC6A2
SCHEMBL13657611 0.76 KMT2A (0.44) HRH1HTR2ALMNASLC6A2SLC6A4
SCHEMBL28759613 0.75 KMT2A (0.46) HTR2ATDP1LMNASMN1; SMN2NFKB1
SCHEMBL1978757 0.74 SLC6A2 (0.49) HTR2ASLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL4130129 0.74 KMT2A (0.41) LMNASMN1; SMN2CYP2D6AOC3KMT2A
SCHEMBL3028964 0.74 TAAR1 (0.43) HRH1HTR2ATDP1LMNASMN1; SMN2
Hydrochloric Acid SCHEMBL10915686 0.73 TDP1 (0.41) HRH1HTR2ATDP1LMNASMN1; SMN2
Brompheniramine SCHEMBL1901052 0.73 CHRM2 (0.88) HRH1HTR2ALMNASLC6A2SLC6A4
Brompheniramine SCHEMBL28086361 0.73 CHRM2 (0.88) HRH1HTR2ALMNASLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090124610-A1 PHARMACEUTICAL COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124610-A1 PHARMACEUTICAL COMPOUNDS GRK3, GRK4, CDK1 HRH1 957/4885HTR2A 984/4885TDP1 2674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.